Alto Neuroscience, Inc.
ANRO
$3.14
$0.020.64%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.56M | 5.70M | 6.20M | 5.83M | 5.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.68M | 15.68M | 17.00M | 18.89M | 18.34M |
| Operating Income | -18.68M | -15.68M | -17.00M | -18.89M | -18.34M |
| Income Before Tax | -17.71M | -15.17M | -15.20M | -16.78M | -16.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.71M | -15.17M | -15.20M | -16.78M | -16.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.71M | -15.17M | -15.20M | -16.78M | -16.03M |
| EBIT | -18.68M | -15.68M | -17.00M | -18.89M | -18.34M |
| EBITDA | -18.51M | -15.51M | -16.83M | -18.76M | -18.23M |
| EPS Basic | -0.65 | -0.56 | -0.57 | -0.62 | -0.60 |
| Normalized Basic EPS | -0.41 | -0.33 | -0.35 | -0.39 | -0.37 |
| EPS Diluted | -0.65 | -0.56 | -0.57 | -0.62 | -0.60 |
| Normalized Diluted EPS | -0.41 | -0.33 | -0.35 | -0.39 | -0.37 |
| Average Basic Shares Outstanding | 27.07M | 27.05M | 26.77M | 26.96M | 26.91M |
| Average Diluted Shares Outstanding | 27.07M | 27.05M | 26.77M | 26.96M | 26.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |